-未治療のFLT3遺伝子変異陽性急性骨髄性白血病患者に対する第I相試験の最新成績も -

 アステラス製薬株式会社(本社:東京、代表取締役社長CEO:安川 健司、以下「アステラス製薬」)は、2018年12月1日から4日に米国サンディエゴで開催される第60回米国血液学会(American Society of Hematology: ASH)の年次総会において、急性骨髄性白血病治療剤として開発中のギルテリチニブに関し、未治療のFLT3遺伝子変異陽性急性骨髄性白血病(Acute Myeloid Leukemia: AML)患者に対する寛解導入療法および地固め療法との併用第I相試験の最新成績を含むAML の研究結果について発表しますので、お知らせします。

 以下の演題が口頭発表される予定です。

Title: Updated Results From a Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) (Abstract 564)

Presenter: Keith W. Pratz, M.D., John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

  • Session Date/Time: Monday, December 3, 8:15 a.m. PST
  • Location: Manchester Grand Hyatt, Seaport Ballroom F

 以下の3つの演題がポスター発表される予定です。

Title: Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission With Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment With Gilteritinib in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With FLT3 Mutations (Abstract 1458)

Lead Author: Mark J. Levis, M.D., Ph.D., John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

  • Session Date/Time: Saturday, December 1, 6:15 p.m. PST
  • Location: San Diego Convention Center, Hall GH


Title: Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings From the Safety Cohort (Abstract 2376)

Lead Author: Jordi Esteve, M.D. Ph.D., Hospital Clínic de Barcelona, Barcelona, Spain

  • Session Date/Time: Sunday, December 2, 6:00 p.m. PST
  • Location: San Diego Convention Center, Hall GH

Title: Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients With Relapsed/Refractory (R/R) FLT3-Mutated (FLT3mut) and FLT3-Wild Type (FLT3wt) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study (Abstract 4824)

Presenter: James D. Griffin, M.D., Dana-Farber Cancer Institute, Boston 

  • Session Date/Time: Monday, December 3, 6:00 p.m. PST
  • Location: San Diego Convention Center, Hall GH

 また、アステラス製薬は、ASHの前日に開催されるFriday Satellite Symposia (FSS) において、以下のシンポジウムを開催します。

Title: Moving Toward Precision Therapy for Patients with AML: Clinical Challenges and Future Directions  

  • Session Date/Time: Friday, November 30, 12:30 p.m. PST
  • Location: Marriott, San Diego Ballroom 

Title: Novel Therapies for AML: Expanding Future Options

  • Session Date/Time: Friday, November 30, 12:30 p.m. PST
  • Location: San Diego Convention Center, Room 1AB

以上